Endocrinology and Metabolism

Bulent Okan Yildiz

1 Article

Obesity and Metabolism
An Update on Contraception in Polycystic Ovary Syndrome: Seda Hanife Oguz, Bulent Okan Yildiz; Endocrinol Metab. 2021;36(2):296-311. Published online April 15, 2021; DOI: https://doi.org/10.3803/EnM.2021.958

11,958 View
755 Download
14 Web of Science
16 Crossref

Polycystic ovary syndrome (PCOS) is a common endocrine disorder in reproductive-aged women, characterized by hyperandrogenism, oligo/anovulation, and polycystic ovarian morphology. Combined oral contraceptives (COCs), along with lifestyle modifications, represent the first-line medical treatment for the long-term management of PCOS. Containing low doses of estrogen and different types of progestin, COCs restore menstrual cyclicity, improve hyperandrogenism, and provide additional benefits such as reducing the risk of endometrial cancer. However, potential cardiometabolic risk associated with these agents has been a concern. COCs increase the risk of venous thromboembolism (VTE), related both to the dose of estrogen and the type of progestin involved. Arterial thrombotic events related to COC use occur much less frequently, and usually not a concern for young patients. All patients diagnosed with PCOS should be carefully evaluated for cardiometabolic risk factors at baseline, before initiating a COC. Age, smoking, obesity, glucose intolerance or diabetes, hypertension, dyslipidemia, thrombophilia, and family history of VTE should be recorded. Patients should be re-assessed at consecutive visits, more closely if any baseline cardiometabolic risk factor is present. Individual risk assessment is the key in order to avoid unfavorable outcomes related to COC use in women with PCOS.

Citations

Citations to this article as recorded by

Clinical management of androgen excess and defect in women
Elena Rosato, Francesca Sciarra, Marianna Minnetti, Anisa Degjoni, Mary Anna Venneri
Expert Review of Endocrinology & Metabolism.2024; 19(1): 21. CrossRef
Il rischio tromboembolico nella sindrome dell’ovaio policistico
Davide Ceccato, Francesca Dassie, Pietro Maffei, Roberto Mioni
L'Endocrinologo.2024; 25(2): 151. CrossRef
Systematic exploration of network pharmacology, in silico modeling and pharmacokinetic profiling for vitamin E in polycystic ovarian syndrome
Rukaiah Fatma Begum, Sumithra Mohan
Future Science OA.2024;[Epub] CrossRef
Current and emerging drug treatment strategies for polycystic ovary syndrome
Nafiye Helvaci, Bulent Okan Yildiz
Expert Opinion on Pharmacotherapy.2023; 24(1): 105. CrossRef
Weighted Gene Co-Expression Network Analysis (WGCNA) Discovered Novel Long Non-Coding RNAs for Polycystic Ovary Syndrome
Roozbeh Heidarzadehpilehrood, Maryam Pirhoushiaran, Malina Binti Osman, Habibah Abdul Hamid, King-Hwa Ling
Biomedicines.2023; 11(2): 518. CrossRef
The mechanism of Leonuri Herba in improving polycystic ovary syndrome was analyzed based on network pharmacology and molecular docking
Mali Wu, Hua Liu, Jie Zhang, Fangfang Dai, Yiping Gong, Yanxiang Cheng
Journal of Pharmacy & Pharmaceutical Sciences.2023;[Epub] CrossRef
Evaluation of the efficacy of an antioxidant combination for the modulation of metabolic, endocrine, and clinical parameters in patients with polycystic ovary syndrome
Carmen Pingarrón Santofímia, Silvia Poyo Torcal, Helena López Verdú, Alexandra Henríquez Linares, Virginia Calvente Aguilar, Pablo Terol Sánchez, María Sol Martínez García, Pilar Lafuente González
Gynecological Endocrinology.2023;[Epub] CrossRef
Contemporary Management of the Patient with Polycystic Ovary Syndrome
Nicolás Omar Francone, Tia Ramirez, Christina E. Boots
Obstetrics and Gynecology Clinics of North America.2023; 50(4): 695. CrossRef
Challenges in diagnosis and health care in polycystic ovary syndrome in Canada: a patient view to improve health care
Beate C. Sydora, Michaelann S. Wilke, Maggie McPherson, Sarah Chambers, Mahua Ghosh, Donna F. Vine
BMC Women's Health.2023;[Epub] CrossRef
Effect of Berberine Phytosome on reproductive, dermatologic, and metabolic characteristics in women with polycystic ovary syndrome: a controlled, randomized, multi-centric, open-label clinical trial
Francesco Di Pierro, Ruqqia Sultana, Amna Zia Eusaph, Saida Abrar, Mahroo Bugti, Fauzia Afridi, Umer Farooq, Somia Iqtadar, Fareeha Ghauri, Syeda Makhduma, Shazia Nourin, Ayesha Kanwal, Aasiya Bano, Ali Akbar Bugti, Shah Mureed, Ayesha Ghazal, Romana Irsh
Frontiers in Pharmacology.2023;[Epub] CrossRef
Investigation of taste function and eating behavior in women with polycystic ovary syndrome
Sila Cetik, Aylin Acikgoz, Bulent Okan Yildiz
Appetite.2022; 168: 105776. CrossRef
microRNAs and long non‐coding RNAs as biomarkers for polycystic ovary syndrome
Mona Tamaddon, Mostafa Azimzadeh, Seyed Mohammad Tavangar
Journal of Cellular and Molecular Medicine.2022; 26(3): 654. CrossRef
Effect of orlistat during individualized comprehensive life-style intervention on visceral fat in overweight or obese PCOS patients
Min Min, Xiangyan Ruan, Husheng Wang, Jiaojiao Cheng, Suiyu Luo, Zhongting Xu, Meng Li, Alfred Otto Mueck
Gynecological Endocrinology.2022; 38(8): 676. CrossRef
Effect of metformin and exenatide on pregnancy rate and pregnancy outcomes in overweight or obese infertility PCOS women: long-term follow-up of an RCT
Renyuan Li, Tingting Mai, Siyuan Zheng, Ying Zhang
Archives of Gynecology and Obstetrics.2022; 306(5): 1711. CrossRef
Oral contraceptives and stroke: Foes or friends
Varun Reddy, Megan Wurtz, Shahil H. Patel, Micheline McCarthy, Ami P. Raval
Frontiers in Neuroendocrinology.2022; 67: 101016. CrossRef
Clinical profiling of polycystic ovary syndrome patients in Kashmir population
Ahila Ashraf, Rajesh Singh, Shahnawaz Mir
Matrix Science Pharma.2022; 6(1): 23. CrossRef

Author index